Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Advanced Pancreatic Adenocarcinoma: early-phase trial registry

3 of 8 indexed Advanced Pancreatic Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Advanced Pancreatic Adenocarcinoma: 8 US clinical trials tracked, 3 recruiting.

Advanced Pancreatic Adenocarcinoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Brandon Huffman, MD, running 1 of these trials.

Enrollment posture brief

Registry condition advanced-pancreatic-adenocarcinoma

OPEN 3 | RECR 38% | LATE 0 | EARLY 6 | RANK #2176 | SPON 1

Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)

Activity, Motor75%Achalasia50%Advanced Pancreatic Aden (th…38%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Advanced Pancreatic Adenocarcinoma

Advanced Pancreatic Adenocarcinoma lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Pancreatic Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Pancreatic Adenocarcinoma is recruiting below its size-band peers.

    3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Advanced Pancreatic Adenocarcinoma trials is spread across many organizations.

    Brandon Huffman, MD accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Advanced Pancreatic Adenocarcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 25 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.

  4. Advanced Pancreatic Adenocarcinoma research is mostly interventional.

    7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 22

Open and recent trials

8 total, page 1 of 1

RECRUITING 800 participants

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

University of Rochester

NCT06073431

RECRUITING Phase 1 100 participants

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Dana-Farber Cancer Institute

NCT04789486

RECRUITING Phase 1 19 participants

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

City of Hope Medical Center

NCT06454383

ACTIVE NOT RECRUITING NA 25 participants

Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study

M.D. Anderson Cancer Center

NCT04837118

ACTIVE NOT RECRUITING Phase 1 14 participants

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

National Cancer Institute (NCI)

NCT04616534

ACTIVE NOT RECRUITING Phase 2 12 participants

ZN-c3 + Gemcitabine in Pancreatic Cancer

Brandon Huffman, MD

NCT06015659

COMPLETED Phase 1 120 participants

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Novartis Pharmaceuticals

NCT01576666

COMPLETED Phase 2 10 participants

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Emory University

NCT04524702

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2

Named interventions

Most-linked intervention names on Advanced Pancreatic Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Gemcitabine Drug
3 trials
Biospecimen Collection Procedure
3 trials
Computed Tomography Procedure
2 trials
BKM120 Drug
1 trials
LDE225 Drug
1 trials
Elimusertib Drug
1 trials
Gemzar Drug
1 trials
Zentalis Drug
1 trials

US sites by state

Facility locations filed on Advanced Pancreatic Adenocarcinoma trials. A trial with sites in several states counts in each.

Massachusetts 4 trials
Texas 2 trials
California 2 trials
Utah 1 trials
Pennsylvania 1 trials
Oregon 1 trials
North Carolina 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Advanced Pancreatic Adenocarcinoma page

8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Advanced Pancreatic Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Brandon Huffman, MD sponsors the most Advanced Pancreatic Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Brandon Huffman, MD's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Pancreatic Adenocarcinoma condition card totals 8 registered trials; most-linked intervention Gemcitabine; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.